Skip to main content
Clinical Trials/NCT05638971
NCT05638971
Completed
Not Applicable

Optical Detection Infiltration/Extravasation in Neonates, a Continuous Monitoring for Peripheral Venous Accesses.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1 site in 1 country50 target enrollmentAugust 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Extravasation Injury
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
50
Locations
1
Primary Endpoint
TIME
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Peripheral intravenous (PIV) therapy is one of the most common invasive procedures performed in hospitals. PIV failures often occur when fluids leak out of the vein into surrounding tissue. This failure is usually called infiltration if the leakage involves non-vesicant solutions or extravasation in case of vesicant solutions. In this clinical study both infiltration and extravasation events are indicated by the term "infiltration".

neonatal intensive care unit patients are an high-risk population for infiltration due to their intrinsic characteristic: poor and fragile vein asset, frequent and uncontrolled movements, need for prolonged intravenous drug and fluid administration. Current nursing practice involves regular PIV site assessments for continuous infusions; particular attention is payed to the identification of swelling, pain, redness, warmth, or coolness. As infiltration represents a leading cause of iatrogenic injury, an early identification, an early identification can minimize its consequences.

The ivWatch Model 400 is a device that assists medical professionals in monitoring patients for PIV infiltrations using an optical sensor. This device received FDA clearance and European Conformity Mark for use in the adult and pediatric age groups. ivWatch enhanced the Model 400 to support a new disposable electronic sensor (SmartTouch sensor). In this study, the SmartTouch Sensor will be tested in a neonatal population in a NICU setting. The new sensor design includes optical components in the sensor package, similar to a typical pulse oximeter.

Primary study objective is to investigate whether the ivWatch SmartTouch sensor may be helpful in early identification of any kind of infiltration, if compared with our current standards of care.

Registry
clinicaltrials.gov
Start Date
August 1, 2021
End Date
July 12, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

D ANDREA VITO

Principal Investigator

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Eligibility Criteria

Inclusion Criteria

  • Term and pre-term infants;
  • birth weight \> 1.5 kg;
  • need for continuous IV therapy with an expected duration \> 24 hours.

Exclusion Criteria

  • birth weight \</= 1.5 kg;
  • non continuous IV therapy;
  • IV therapy expected duration \</= 24 hours;
  • skin disorders.

Outcomes

Primary Outcomes

TIME

Time Frame: through study completion, an average of 30 hours

How many times the ivWatch detect infiltrations before nurses. The degree of injury is calculated on the Millian scale.

Secondary Outcomes

  • TIME 2(through study completion, an average of 30 hours)

Study Sites (1)

Loading locations...

Similar Trials